

----- PRESS RELEASE -----

Herpen, The Netherlands, January 27, 2025

Life Sciences company Orexa raises investments of € 625,000

HERPEN, THE NETHERLANDS - Orexa B.V., a Dutch life sciences company that is developing a new medicine that increases food intake and supports health in patients, has completed a financing round of € 625,000. The investment will be used to expedite Orexa's clinical phase 2 program.

The first clinical phase 2 study, in the prevention of post-operative ileus, is running in three hospitals in Germany. The first interim results are expected in H1-2025. In addition, Orexa has two other phase 2 studies in preparation: in hospitalized anorexia patients and a study focused on underweight elderly people.

Orexa has raised a total of € 4.3 million in capital since 2022. Orexa wants to conduct phase 2 studies in three indications in order to identify the clinical condition(s) in which the most health benefits can be obtained. For the further development of the candidate drug, Orexa is in discussion with a number of potential development partners.

About Orexa:

Orexa is developing a drug that increases food intake. The markets where increased food intake can lead to substantial health benefits are large. Orexa focuses primarily on the recovery of patients who have undergone surgery, anorexia patients and elderly people with malnutrition (sarcopenia). The company is founded in 2016 and is based in Herpen (North Brabant), The Netherlands. For more information, see www.orexa.eu.